Related to Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks

• Alcon Concludes Novartis’ $11.2B Acquisition Bid Is Grossly Inadequate
  
• Japan Sanctions Three Novartis Drugs for Hypertension, Advanced Renal Cancer, and Type 2 Diabetes
  
• Juvaris Rakes In $25M to Advance Adjuvant Development
  
• Life Technologies Gains on Race toward $1,000 Genome
  
• U87MG Glioblastoma Cell Line Sequenced in Under a Month
  
• Oxford Nanopore Secures About $27.73M to Progress Nanopore-Based Label-Free Sequencing Platform
  
• Nanotech-Based DNA Sequencer that Distinguishes between the Four Bases Developed
  
• Immune Targeting System Adds £8.65M to Series A Funds to Take Universal Flu Vaccine through Phase II
  
• NABsys Pockets $7M to Progress Solid-State DNA Sequencing Platform
  
• FDA Sanctions Novartis’ Vaccine for Meningococcal Disease in Adolescents and Adults
  
• $25M NSF Center Set Up to Investigate Complex Biological Systems
  
• Life Technologies Introduces Nanocrystal-Based Single Molecule Sequencing Technology
  
• Life Technologies, The Translation Genomics Research Institute, and US Oncology to Conduct Breast Cancer Sequencing Project
  
• Institute for Systems Biology Uses Complete Genomics’ Sequencing Service to Validate Miller Syndrome Gene
  
• Investigator Pinpoints Gene that Causes Charcot-Marie-Tooth Disease
  
• Fraunhofer USA CMB Obtains $4.4M DARPA Funding for Phase I Trials with H1N1 Vaccine
  
• Ambry to Offer Sequence-Enrichment Capabilities with RainDance’s RDT1000 Platform
  
• EC Clears Novartis’ Quadrivalent Meningitis Vaccine
  
• Researchers Engineer Mosquitoes into “Flying Vaccinators”
  
• The Integrated Biobank of Luxembourg to Leverage Life Technologies’ Sequencing System